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Abstract
Purpose In a minority of cases a definite diagnosis and
stage grouping in cancer patients is not possible based on
the imaging information of PET/CT. We report our
experience with percutaneous PET/CT-guided bone biop-
sies to histologically verify the aetiology of hypermetabolic
bone lesions.
Methods We retrospectively reviewed the data of 20
consecutive patients who underwent multimodal image-
guided bone biopsies using a dedicated PET/CT system in a
step-by-step technique. Technical and clinical success rates
of PET/CT-guided biopsies were evaluated. Questionnaires
were sent to the referring physicians to assess the impact of
biopsies on patient management and to check the clinical
need for PET/CT-guided biopsies.
Results Clinical indications for biopsy were to histologi-
cally verify the aetiology of metabolically active bone
lesions without a morphological correlate confirming the
suspicion of metastases in 15 patients, to determine the
origin of suspected metastases in 3 patients and to evaluate
the appropriateness of targeted therapy options in 2
patients. Biopsies were technically successful in all
patients. In 19 of 20 patients a definite histological
diagnosis was possible. No complications or adverse effects
occurred. The result of PET/CT-guided bone biopsies
determined a change of the planned treatment in overall
56% of patients, with intramodality changes, e.g. chemo-
therapy with palliative instead of curative intent, and
intermodality changes, e.g. systemic therapy instead of
surgery, in 22 and 50%, respectively.
Conclusion PET/CT-guided bone biopsies are a promising
alternative to conventional techniques to make metaboli-
cally active bone lesions—especially without a distinctive
morphological correlate—accessible for histological verifi-
cation. PET/CT-guided biopsies had a major clinical impact
in patients who otherwise cannot be reliably stage grouped
at the time of treatment decisions.
Keywords Image-guided bone biopsy . PET/CT-guided
biopsy . Positron emission tomography . Breast cancer .
Clinical impact
Introduction
The accurate definition of tumour stages is a prerequisite
for an individualized, risk-adapted therapy of cancer
patients. In this context, the recognition and verification
of distant metastatic disease is of utmost importance, as
patients with distant metastases usually have incurable
disease. Local and systemic therapy of patients in a
palliative situation tends to be less aggressive and associ-
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ated with fewer side effects than therapies used with
curative intent. Therefore, optimal staging may prevent
patients with distant metastatic disease from receiving futile
but burdensome therapies at the expense of quality of life.
PET/CT with 18F-fluorodeoxyglucose (FDG) offers
excellent diagnostic accuracy for staging and restaging of
a wide range of malignant tumours, among these non-
small cell lung cancer (NSCLC), lymphoma, breast cancer
and melanoma. The additional information provided by
PET/CT compared with conventional staging has a major
impact on treatment decisions in up to one third of patients
[1–8]. However, the accumulation of FDG is not tumour
specific, but FDG uptake can also occur in a number of
benign conditions. Benign tumours, post-traumatic situa-
tions and inflammatory changes may mimic metastatic
disease. False-positive reporting of such findings may lead
to an overstaging and undertreatment of patients. On the
other hand false-negative reporting may lead to a futile
curative approach at the cost of quality of life in patients
effectively in a palliative situation. To provide an
objective fundament for treatment decisions, histological
verification of lesions depicted by PET may be regarded
as mandatory, for example in cases of singular occurrence
of potentially stage determining findings and/or when
confirmative morphological changes do not support the
presumed diagnosis.
Percutaneous biopsies with image guidance by CT are
well established and effectively used in routine clinical
practice as minimally invasive alternatives to open surgical
biopsies, with success rates reported for biopsies of
morphologically clearly circumscribed lesions between 70
and 90% [9, 10]. However, metabolically active lesions
without a distinctive morphological correlate are not or not
reliably accessible to CT-guided biopsy and the rate of
false-negative biopsies of such lesions may be substantially
higher. To overcome these limitations we developed an
approach for multimodal image-guided interventions using
the metabolic and topographic information of PET together
with CT navigation [11]. We report on our experience in
patients who underwent PET/CT-guided bone biopsies for
metabolically active lesions and discuss the clinical impact
and applications of the method based on a survey of
referring physicians.
Materials and methods
Patients
A total of 20 consecutive patients (15 female and 5 male)
assigned to the Department of Nuclear Medicine for FDG
PET/CT in the course of primary staging (n=10) or
restaging (n=10) of malignancies underwent PET/CT-
guided bone biopsies of metabolically active lesions
suspicious for metastatic disease. Patients suffered from
breast cancer (n=9), NSCLC (n=5), melanoma (n=2),
uterine leiomyosarcoma (n=1) (Fig. 1), ovarian cancer
(n=1) or lymphoma (n=1). One patient had a history of
more than one primary tumour, i.e. melanoma and uterine
leiomyosarcoma (Table 1). The median age of the patients
was 58 years (mean: 56 years, range: 41–72 years). All
patients gave written consent before the intervention and
patient data were retrospectively reviewed in accordance
with the regulations of the local Ethics Committee.
FDG PET/CT
PET/CT acquisitions were performed with an integrated
PET/CT system (Biograph 16 HI-REZ, Siemens Medical
Solutions). All patients fasted for at least 6 h and blood
glucose level was below 10 mmol/l before intravenous
injection of 5–7 MBq FDG/kg body weight. Emission
images were obtained 90 min after injection (3 min per
bed position, scan length 16.2 cm per bed position) from
the neck to the pelvis (5–7 bed positions) and were
coregistered with an unenhanced CT of the same region
(120 kV, 80mAs, reconstructed slice thickness 2 mm).
Images were evaluated qualitatively in a routine clinical
setting. No definite SUV cut-off values for the distinction
of benign from malignant lesions were applied. Lesions
were evaluated with respect to the metabolic properties of
the primary tumour and/or the expected FDG uptake
according to the tumour type. Patients with focal bone
FDG uptake without morphological correlate or without
confirmative structural changes on CT were considered
candidates for PET/CT-guided biopsy when other PET/CT
findings did not support the suspicion of distant metasta-
ses, and when no benign reason of metabolic changes was
evident.
PET/CT-guided bone biopsy
PET/CT-guided bone biopsies were performed in a step-by-
step technique according to a protocol previously published
[11]. Interventions were either performed on the day of
PET/CT subsequently to the diagnostic examination or
were scheduled on a separate day. If done on the same day,
a single-bed PET/CT acquisition of the region concerned
was repeated 120–180 min after injection of the radiophar-
maceutical. No additional activity was given, but the
acquisition time was prolonged to 5 min per bed position
to assure adequate image quality. For interventions on a
separate day a reduced dose of 3–5 MBq FDG/kg body
weight was injected and the acquisition time for a single-
bed PET/CT was prolonged to 5 min per bed position
90 min after injection.
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Patients were positioned in a prone or supine position
depending on the localization of the lesion concerned, a
single bed PET/CT acquisition of the region of interest was
obtained and the access path was defined based on the
PET/CT presentation of the metabolically active lesion of
interest. Interventions were performed under aseptic con-
ditions, local anaesthesia and sedation with midazolam, if
necessary. The needle was introduced stepwise under CT
guidance. If reasonable, the correct needle position in the
centre of the hypermetabolic lesion was assured by a
repeated single-bed PET/CT acquisition with the biopsy kit
in place before sampling, and the biopsy needle was
repositioned, if necessary. Depending on the localization
and depth of the lesion either a 15G (Bonopty, AprioMed,
Uppsala, Sweden) or a 10G (Promedics, Biel, Switzerland)
bone biopsy kit was chosen. One or more samples were
obtained in each patient, and histopathology and immuno-
histochemistry of each specimen was performed.
Questionnaires
Questionnaires were sent to the attending physicians to
determine the clinical impact of PET/CT-guided biopsies on
the planned treatment strategy. Planned treatment based on
information available after FDG PET/CT (surgery, radio-
therapy, chemotherapy and other treatment options such as
endocrine therapy or bisphosphonates) and changes of the
treatment plan after PET/CT-guided bone biopsies were
recorded. The relevance of additional information gained
by biopsies for confidence in diagnoses and treatment
decisions as well as for patient communication was defined.
In addition, we requested a general assessment of PET/CT-
guided interventions as a recently established part of the
department’s range of services and of its influence on
clinical practice.
Results
Clinical indication for tissue sampling
Biopsies were indicated in 15 patients to clarify the
aetiology of unexpected focal bone FDG uptake that did
not demonstrate confirmative morphological changes and/
or was the sole sign of distant metastases. In two of these
patients a benign diagnosis was favoured before biopsy
Fig. 1 A 58-year-old women with newly diagnosed uterine leiomyosarcoma. FDG PET/CT detected a solitary lesion with focally increased
uptake in the left sacrum. Histological examination confirmed a bone metastasis of the uterine leiomyosarcoma
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based on imaging findings and clinical history, i.e.
sarcoidosis and spondylodiscitis, and biopsy was performed
to rule out malignancy before onset of therapy.
PET/CT-guided biopsy was indicated to histologically
determine the origin of bone metastases in one patient with
a history of two primary tumours and in two patients when
PET/CT raised the suspicion of a second primary tumour.
In two patients tissue sampling and characterization were
requested to evaluate the appropriateness of targeted
therapy options.
PET/CT-guided bone biopsy
The hypermetabolic bone lesions of interest were success-
fully targeted and representative tissue samples of the
metabolically active sites could be obtained in all patients
(n=20). Bone metastases were confirmed in 14 of 15
patients who presented with FDG-avid lesions that
appeared morphologically unremarkable or ambiguous on
CT. Both patients with a benign diagnosis previously
postulated based on imaging findings had bone metastases.
One of these patients with a spondylodiscitis previously
suspected on magnetic resonance imaging (MRI) received
systemic therapy after verification of a tumour recurrence.
In the other patient with NSCLC, findings on PET/CT were
regarded compatible with a pulmonary and bone sarcoido-
sis, but biopsy confirmed the palliative situation with bone
metastases. In one patient with newly diagnosed NSCLC, a
suspected bone metastasis in the ilium was confirmed to
represent an inflammatory process, and treatment with
curative intent was initiated.
The origin of metastases could be determined in two of
three patients with more than one primary tumour known or
suspected before biopsy. In the third patient the histological
examination revealed a metastasis, but the origin could not
be determined by the immunohistochemistry profile.
Representative tissue samples for characterization of
metastases could be provided in two patients biopsied to
evaluate the appropriateness of targeted therapy options,
e.g. hormone receptor and HER2/neu status of the
metastasis before onset of a treatment with an aromatase
inhibitor and/or trastuzumab.
Table 1 Patient characteristics and punctures
Diagnosis Indication for
PET/CT
Localization of
biopsy
Lesion Histology Success
Diameter Depth Technical Clinical
1 Breast cancer Primary staging L5 8 mm 11 cm Breast cancer Yes Yes
2 Breast cancer Recurrence Scapula 8 mm 3 cm Breast cancer Yes Yes
3 Breast cancer Recurrence Acetabulum 12 mma 10 cm Breast cancer Yes Yes
4 NSCLC, DD sarcoidosis Primary staging T8 10 mm 7 cm NSCLC Yes Yes
5 Breast cancer, DD NSCLC Recurrence T6 24 mma 8 cm Adenocarcinomab Yes Nob
6 NSCLC Primary staging Sacroiliac joint 10 mm 6 cm Inflammation Yes Yes
7 Melanoma, uterine
leiomyosarcoma
Recurrence Trochanter 24 mma 5 cm Uterine
leiomyosarcoma
Yes Yes
8 Uterine leiomyosarcoma Primary staging S1 8 mma 7 cm Uterine
leiomyosarcoma
Yes Yes
9 Melanoma Recurrence Os ilium 30 mm 4 cm Melanoma Yes Yes
10 NSCLC During
chemotherapy
5th rib 12 mma 3 cm NSCLC Yes Yes
11 Ovarian cancer Recurrence L3 30 mm 9 cm Ovarian cancer Yes Yes
12 Melanoma Follow-up Os ischium 10 mm 11 cm Prostate cancer Yes Yes
13 NSCLC Primary staging Os ilium 28 mm 9 cm NSCLC Yes Yes
14 Breast cancer Primary staging T12 17 mm 9 cm Breast cancer Yes Yes
15 Hodgkin’s lymphoma Primary staging S2/S3 18 mma 6 cm Hodgkin’s
lymphoma
Yes Yes
16 Breast cancer Recurrence Sacrum 20 mma 6 cm Breast cancer Yes Yes
17 NSCLC Primary staging L1 28 mm 4 cm NSCLC Yes Yes
18 Breast cancer Primary staging Symphysis 17 mm 2 cm Breast cancer Yes Yes
19 Breast cancer, DD
spondylodiscitis
Recurrence S1 28 mma 7 cm Breast cancer Yes Yes
20 Breast cancer Recurrence 8th rib 10 mm 3 cm Breast cancer Yes Yes
a Not delineable based on CT information; diameter estimated based on the PET appearance alone (diameter at a threshold value of 70% of SUVmax)
b Determination of the primary tumour not possible due to negative immunohistochemistry
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Of all 20 biopsies performed because of the unclear
nature of FDG-avid bone lesions (n=15), to determine the
origin of metastases in patients with more than one
(suspected) primary tumour (n=3), or to evaluate for the
appropriateness of targeted therapies (n=2), bone lesions
did not show a morphological CT correlate in 8 patients,
and in 11 patients the lesions punctured presented an
indeterminate and/or unreliably delineable morphological
appearance on CT. The size of metabolically active lesions
without a distinctive morphological correlate was measured
on CT, as far as lesions were morphologically traceable
aware of the PET information (n=11). The diameter of
lesions without any CT correlate was estimated based on
the PET appearance alone (diameter of the FDG-avid lesion
measured at a threshold value of 70% of SUVmax, n=8).
The median diameter of all lesions punctured was 17 mm
(mean: 18 mm, range: 8–30 mm). One patient had a
sclerotic lesion clearly delineable on CT (diameter 10 mm,
Fig. 2). The median length of the access path was 6.3 cm
(mean: 6.5 cm, range: 2–11 cm). Lesions were located in
the spine in six, in the pelvic bones in ten, in a rib in two
and in the scapula and femur in one patient, respectively
(Table 1). Total intervention time varied between 40 and
70 min, depending on the localization of biopsies and the
necessity of repeated PET/CT acquisitions to assure correct
sampling of the metabolically active lesion.
Side effects and complications
Of 20 patients, 17 were treated on an outpatient basis and
could be released on average 1 h after completion of the
intervention; 3 were scheduled for biopsy during hospital-
ization. Interventions were well tolerated under local
anaesthesia. Three patients with claustrophobia had mid-
azolam 2–5 mg for short-term sedation. No near-term
adverse effects (e.g. major bleeding, pneumothorax, infec-
tion) occurred in any patient, and all patients were released
in good physical status. No complications during follow-up
were reported in the questionnaires.
Clinical value of PET/CT-guided biopsies
Questionnaires were completed and returned by 13 of 15 of
the attending physicians for 18 of 20 patients (response rate
90%). Changes of the original treatment plan after PET/CT-
guided biopsies are listed in Table 2. Based on the available
Fig. 2 Follow-up examination of a 67-year-old patient with a history
of malignant melanoma. FDG PET/CT showed an unexpected FDG-
avid lesion in the periphery of the prostate and a singular FDG-avid
sclerotic lesion in the left ischium. Bone biopsy revealed a metastasis
of prostate cancer and confirmed the presence of a second primary
tumour
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information a treatment decision was not possible, and
further investigations were regarded as necessary in 44% of
patients after PET/CT and in 1 of 20 patients (6%, primary
tumour unclear according to histopathology and immuno-
histochemistry) after PET/CT-guided biopsy. Overall, the
treatment plan was modified after biopsy in 56% of
patients, with intramodality changes, e.g. chemotherapy
with palliative instead of curative intent, and intermodality
changes, e.g. systemic therapy instead of surgery, in 22 and
50%, respectively. In eight patients the histological result of
biopsies did not modify planned treatment, but the
confidence in treatment decisions was increased in all
cases. The relevance of information gained by biopsies to
communicate treatment options with the patient was
categorized as high or very high in 83%, moderate in
11% and low in 6%.
All referring physicians interviewed judged PET/CT-
guided biopsies as a reasonable complement to the
diagnostic spectrum of our department. Of those, 61%
generally appreciated the possibility of a one-stop shop
comprising PET/CT and histological verification of suspi-
cious findings, and 41% valued PET/CT-guided biopsies in
selected cases, i.e. when lesions cannot be reliably targeted
by other means.
Discussion
PET/CT has evolved as the standard of care imaging
modality in the diagnostic work-up of many tumours
[12, 13] and clarifies true stage grouping in up to one third
of patients compared with conventional staging [2, 6, 8, 14,
15]. Despite the excellent diagnostic accuracy of PET/CT,
it remains impossible in a number of patients with focal
tracer uptake in the skeleton to reliably determine the
tumour stage based on the imaging information alone. A
number of benign bone tumours such as fibrous dysplasia
[16–19], Paget disease [20], sarcoidosis [21], giant cell
tumours and Langerhans cell histiocytosis [16] have been
described to show FDG uptake comparable to malignant
bone tumours and eventually can mimic bone metastases
[16, 22]. The same is true for inflammatory and infectious
changes, e.g. Brodie abscesses, atypical appearances of
osteoarthritis and post-traumatic changes that can also
show a variable degree of FDG uptake and occasionally
can be difficult to separate from metastases [22, 23]. It is
evident that the aetiology of such indeterminate findings
on PET/CT must be evaluated prudently before a
treatment decision with curative or palliative intent is
reached, to avoid under- and overtreatment, and conse-
quently to maintain optimal management and quality of
life in cancer patients. This is especially true for solitary
suspected distant metastases and for metabolically active
lesions without confirmative structural changes on the
coregistered CT. MRI provides higher sensitivity than CT
and a diagnostic performance comparable to PET/CT in
the detection of bone metastases and may be considered to
further evaluate suspicious findings [24, 25]. However,
when small, singular and/or ambiguous lesions with a low
or moderate pre-test probability have to be evaluated, even
imaging tests with an overall excellent accuracy such as
PET/CT and MRI may not be regarded as accurate enough
in an individual patient, and it comes to be a question of
“knowing” instead of “guessing” when a decision for a
therapeutic concept with palliative vs curative intent has to
be made. In such cases it is mandatory that suspicious
findings are confirmed histologically.
Image-guided punctures are well established as a
minimally invasive technique to provide tissue samples
for histological work-up of bone lesions. CT-guided
biopsies, for example, allow for successful sampling in
70–90% of cases with morphologically clearly circum-
scribed lesions [9, 10], but the success rate of biopsies may
be substantially lower for lesions that are characterized by
their metabolic properties rather than by structural changes.
Under such circumstances non-representative tissue sam-
pling and false-negative biopsies may occur, especially
when PET imaging and interventions are performed by
different persons, at different time points, using different
devices or when positioning the patient differently. Another
issue in a routine setting may be the reservation of the
interventionist to accept such patients for biopsy, as it is
difficult from the radiologist’s perspective to justify risk
Table 2 Planned treatment and changes of treatment plan after
PET/CT and PET/CT-guided biopsies
Planned treatment after
PET/CT PET/CT-guided biopsy
n % n %
Not defined 8/18 44 1/18 6
Surgery 3/18 17 4/18 22
Radiotherapy 2/18 11 3/18 17
Chemotherapy
Curative intent 1/18 6 1/18 6
Palliative intent 3/18 17 11/18 61
Othera 2/18 11 4/18 22
Changes of treatment plan after
PET/CT-guided biopsy
All 10/18 56
Intramodality 4/18 22
Intermodality 9/18 50
a i.e. endocrine therapy, bisphosphonates
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and complications associated with an intervention in cases
of a lesion with indeterminate or even benign morpholog-
ical appearance.
PET/CT guidance offers the opportunity to directly
puncture the metabolically active lesion irrespective of
structural landmarks, to reliably obtain representative tissue
samples and therefore to avoid futile biopsy attempts. In
situations as illustrated in Figs. 1 and 3, i.e. bone FDG
uptake in morphologically unremarkable or indeterminate
lesions, and without a typical pattern of other lesions
supporting the suspicion of metastases, PET/CT-guided
biopsies allow for a definite diagnosis. Histopathological
verification of suspected metastases may also be necessary
when patients suffer from more than one primary tumour or
when a second primary is suspected based on PET/CT.
Incidental PET findings suggesting a previously unknown
second malignancy were reported to occur in 3–6% of all
patients, and a second primary tumour may be proven in
about one third of those cases [26–28]. An example is
provided in Fig. 2 where the indication for biopsy was to
determine the source of a probable bone metastasis, as the
therapeutic concept would be completely different depend-
ing on the histological result. With the increasing availabil-
ity of individualized tumour-specific therapies, we expect
accordingly a rising demand for the characterization of
metastases before selection of the appropriate therapeutic
agents (Fig. 4). Besides such clinical applications, PET/CT-
guided interventions may serve as an optimal reference
standard in the context of diagnostic studies, as this
technique minimizes the risk of sampling errors compared
to morphology-guided biopsy techniques.
According to our experience, even small lesions without
a CT correlate can be punctured reliably, as the correct
needle positioning can be ascertained by a repeated regional
PET/CT before tissue sampling. A negative histological
result may be regarded as true-negative and a sampling
error can be excluded when the specimen was obtained
after verified needle positioning in the centre of the
metabolically active lesion. In the group of patients
reported, all bone biopsies could be accomplished success-
fully, i.e. the biopsy needle was positioned correctly in the
lesion of interest, and a clinically useful histological result
could be obtained in 95% of patients. The high rate of
metastases was surprising given that many lesions biopsied
Fig. 3 A 61-year-old patient with operated breast cancer. PET/CT staging showed a moderately FDG-avid lesion in the 8th rib on the right with
an indeterminate morphological appearance. PET/CT-guided biopsy revealed a solitary bone metastasis
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were considered of intermediate risk to represent malig-
nancy based on the PET/CT appearance, and a lower rate of
malignant findings might be expected in a larger series.
Overall, patient management was modified according to
the results of PET/CT-guided biopsies in 56% of cases. The
original treatment plan was altered in terms of intramodality
changes in 22% of patients, and the composition of
intended treatment modalities was changed in 50% of
patients. In most cases, intermodality changes were due to
the diagnosis of distant metastatic spread, i.e. the therapeu-
tic concept was shifted from a curative to a palliative
approach. In this context, the availability of a histologically
verified stage grouping was considered relevant or very
relevant for patient communication in 83% of cases, and the
immediate verification of distant metastases prevented
futile therapies with curative intent in more than half of
all patients. In general, PET/CT-guided interventions were
regarded as a reasonable extension of the diagnostic
spectrum of our PET unit, either as an alternative approach
to assess morphologically unremarkable PET findings, and/
or as a diagnostic one-stop shop staging with histological
verification of suspected distant metastases.
PET/CT-guided biopsies were performed in a manner
similar to routine CT-guided punctures, i.e. the lesion of
interest was targeted in a step-by-step technique with
repeated CT control scans to verify the needle position.
Although clinically absolutely reliable, the time needed for
PET/CT-guided interventions in this technique has a
number of drawbacks, e.g. the costs related to the
occupancy of the PET/CT machine, the discomfort for the
patient and the radiation burden for the interventionist
originating from the patient. We are currently evaluating a
dedicated system for computer-aided navigation based on
PET/CT to reduce intervention time and to optimize the
conditions for the routine clinical use of PET/CT-guided
interventions.
Conclusion
PET/CT guidance offers the opportunity to precisely
target even small and morphologically indeterminate bone
lesions for tissue sampling. In a routine setting PET/CT-
guided biopsies had a major clinical impact in patients
Fig. 4 Restaging of a 48-year-old patient with breast cancer. PET/CT
revealed a lymphatic recurrence and a bone metastasis without
morphological correlate in the sacrum. Oestrogen, progesterone and
HER2/neu status of the metastasis was determined by PET/CT-guided
biopsy before therapy decision
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with singular suspected bone metastases, when the
morphological appearance of hypermetabolic lesions did
not support the suspicion of metastases, and to evaluate
the appropriateness of targeted therapy regimens. Besides
this, PET/CT-guided biopsies may serve as a minimally
invasive alternative for representative sampling of meta-
bolically active tissue in the context of diagnostic and
clinical studies.
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